| Reference |
Reference ID |
| Agro KE, Bradley CA, Mittman N, Iskedjian M, Ilersich AL, Einarson TR. Sensitivity analysis in health economic and pharmacoeconomic studies. Pharmacoeconomics 1997;11(1):75-88. |
115 |
| Ament A, Baltussen R. The interpretation of results of economic evaluation: explicating the value of health. Health Economics 1997;6:625-35. |
367 |
| Andersson F. Why is the pharmaceutical industry investing increasing amounts in health economic evaluations? International Journal of Technology Assessment in Health Care 1995;11(4):750-61. |
368 |
| Angrist J. Conditional independence in sample selection models. Economic Letters 1997;54:103-12. |
661 |
| Anis AH, Carruthers G, Carter AO, Kierulf J. Variability in prescription drug utilization: issues for research. Can Med Assoc J 1996;154(5):635-40. |
262 |
| Anonymous. Wrestling with the issues of economic research. Managed Care Marketing 1995;April:32-3. |
381 |
| Anonymous. Cost-effectiveness assumptions "reasonable" at "some point"; CE analyses should avoid using assumptions in making major conclusions - FDA's Woodcock. FDC Reports - The Pink Sheet 1996;58(49):15-6. |
385 |
| Balas EA, Kretschmer RAC, Gnann W, West DA, Boren SA, Centor RM, Nerlich M, Gupta M, West T, Soderstrom NS. Interpreting cost analyses of clinical interventions. JAMA 1998;279(1):54-7. |
363 |
| Beck J, Pauker S. The Markov process in medical diagnosis. Medical Decision Making 1983;3:419-58. |
475 |
| Blades C, Culyer A, Walker A. Health service efficiency: Appraising the appraisers -- a critical review of economic appraisal in practice. Social Science and Medicine 1981;24:461-72. |
670 |
| Blumstein JF. The Oregon experiment: the role of cost-benefit analysis in the allocation of medicaid funds. Social Science and Medicine 1997;45(4):545-54. |
369 |
| Bootman JL; Townsend R; McGhan WF. Principles of pharmacoeconomics. 2nd ed. Cincinnati: Harvey Whitney Books; 1996. |
484 |
| Bootman JL, Harrison DL. Pharmacoeconomics and therapeutic drug monitoring. Pharmacy World and Science 1997;19(4):178-81. |
459 |
| Boyer JG, Pathak DS. Establishing value through pharmacoeconomics: the emerging third objective in clinical trials. Topics in Hospital Pharmacy Management 1994;13(4):1-10. |
460 |
| Bradley CA, Iskedjian M, Lanctot KL, Mittman N, Simone C, St.Pierre, Miller E, Blatman B, Chabursky B, Einarson TR. Quality assessment of economic evaluations in selected pharmacy, medical, and health economics journals. Annals of Pharmacotherapy 1995;29:681-9. |
370 |
| Buring, J.E. and Jonas, M. Large and simple randomized trials. In, Tools for Evaluating Health Technologies. BP-H Washington, DC. Congress, Office of Technology Assessment, U.S. Government Printing Office. 1995. |
487 |
| Cahill NE. Caveats in interpreting and applying pharmacoeconomic data. American Journal of Health-System Pharmacists 1995;52(Suppl 4):24-5. |
428 |
| Campbell D, Stanley J. Gage N, editors.Handbook on Research on Teaching. Chicago: Rand-McNally; 1963;Experimental and Quasi-Experimental Designs for Research on Teaching. p. 171-246. |
667 |
| Canadian Coordinating Office for Health Technology Assessment. Guidelines for Economic Evaluation of Pharmaceuticals. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 1994. |
96 |
| Christiansen CL, Morris CN. Improving the statistical approach to health care provider profiling. Ann Intern Med 1997;127:764-8. |
449 |
| Clemens K, Townsend R, Luscombe F, Mauskopf J, Osterhaus J, Bobula J. Methodological and conduct principles for pharmacoeconomic research. Pharmacoeconomics 1995;8(2):169-74. |
88 |
| Clouse JC. Pharmacoeconomics: a managed care perspective. Topics in Hospital Pharmacy Management 1994;13(4):54-9. |
461 |
| Cook C; Campbell D. Quasi-Experimentation: Design and Analysis Issues for Field Settings. Boston: Houghton-Mifflin; 1981. |
668 |
| Cooke J. The practical impact of pharmacoeconomics on institutional managers. Pharmacoeconomics 1994;6(4):289-97. |
371 |
| Coyle D. Statistical analysis in pharmacoeconomic studies. Pharmacoeconomics 1996;9(6):506-16. |
114 |
| Data JL, Wilke RJ, Barn Clinical Therapeutics 1995;17(1):89-107. |
434 |
| Dreyer EB, Sugar A. Prospective versus retrospective studies. Ophthalmology 1992;99(5):646-7. |
452 |
| Drummond M. Current concerns about economic evaluation. Pharmaceutical Times 1990;February:18-9. |
378 |
| Drummond M, Davies L. Economic analysis alongside clinical trials - revisiting the methodological issues. International Journal of Technology Assessment in Health Care 1991;7(4):561-73. |
380 |
| Drummond M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: is economic evaluation ready for its enhanced status? Health Economics 1992;1:85-92. |
377 |
| Drummond M, Brandt A, Luce BR, Rovira J. Standardizing methodologies for economic evaluation in health care. International Journal of Technology Assessment in Health Care 1993;9(1):26-36. |
142 |
| Drummond M. Evaluation of health technology: economic issues for health policy and policy issues for economic appraisal. Social Science and Medicine 1994;38(12):1593-600. |
376 |
| Drummond M. Guidelines for pharmacoeconomic studies - the way forward. Pharmacoeconomics 1994;6(6):493-7. |
375 |
| Drummond M, Jefferson TO. Guidelines for authors and peer-reviewers of economic submissions to the BMJ. British Medical Journal 1996;313:275-83. |
138 |
| Drummond M. The future of pharmacoeconomics: bridging science and practice. Clinical Therapeutics 1996;18(5):969-78. |
379 |
| Drummond M, Cooke J, Walley T. Economic evaluation under managed competition: evidence from the U.K. Social Science and Medicine 1997;45(4):583-95. |
249 |
| Einarson TR, McGhan WF, Bootman JL. Decision analysis applied to pharmacy practice. American Journal of Hospital Pharmacy 1985;42:364-71. |
382 |
| Else BA, Armstrong EP, Cox ER. Data sources for pharmacoeconomic and health services research. American Journal of Health-System Pharmacists 1997;54:2601-8. |
360 |
| Evans C. The use of consensus methods and expert panels in pharmacoeconomic studies: practical applications and methodological shortcomings. Pharmacoeconomics 1997;12(2 Pt 1):121-9. |
340 |
| Evans RG. Manufacturing consensus, marketing truth: guidelines for economic evaluation. Ann Intern Med 1995;123(1):59-60. |
383 |
| Fayers PM, Hand DJ. Generalisation from phase lll clinical trials: survival, quality of life, and health economics. Lancet 1997;350:1025-7. |
384 |
| Finder S. Providing cost-effective therapy using pharmacoeconomic evaluations: the public sector approach. Clinical Therapeutics 1997;19(1):160-6. |
386 |
| Fowler, F.J. Using patients reports to evaluate medical outcomes. In, Tools for Evaluating Health Technologies. BP-H-142. Washington, DC. Congress, Office of Technology Assessment, US Government Printing Office. 1995. |
485 |
| Freeman RA. Standards for the conduct of industry-sponsored economic and quality of life research. Journal of Research in Pharmaceutical Economics 1992;4(2):15-30. |
387 |
| Frenkel M, Farber MD, Lepe I. Teaching health economics in American medical schools. Journal of Medical Practice Management 1991;7(2):151-4.457Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics 1992;1(1):20-32. |
318 |
| Gagnon, J.P. What constitutes a useful economic study for the pharmaceutical industry. Presented at the Economics and Cost-effectiveness in Evaluating the Value of Cardiovascular Therapies Meeting. Duke Clinical Research Institute. 1997. |
388 |
| Genduso LA, Kotsanos JG. Review of health economic guidelines in the form of regulations, principles, policies and positions. Drug Information Journal 1996;30:1003-16. |
167 |
| Gold MR; Siegel JE; Russell LB, et al. Cost-effectiveness in Health and Medicine. New York, NY: Oxford University Press; 1996. |
471 |
| Gostin L. Health care information and the protection of personal privacy: ethical and legal considerations. Ann Intern Med 1997;127:683-90. |
437 |
| Grabowski H, Mullins CD. Pharmacy benefit management, cost-effectiveness analysis and drug formulary decisions. Social Science and Medicine 1997;45(4):535-44. |
389 |
| Granados A, Jonsson E, Banta H, et al. EUR-ASSESS project subgroup report on dissemination and impact. International Journal of Technology Assessment in Health Care 1997;13(2):220-86. |
361 |
| Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Social Science and Medicine 1997;45(4):563-81. |
390 |
| Haycox A, Drummond M, Walley T. Pharmacoeconomics: integrating economic evaluation into clinical trials. British Journal of Clinical Pharmacology 1997;43:559-62. |
391 |
| Heckman J, Smith J. Assessing the case for social experiments. Journal of Economic Perspectives 1995;9(2):85-110. |
664 |
| Henry D. Australian national drug policy: using cost-effectiveness to gain value for money. Presented at the annual meeting of the International Society of Technology Assessment in Health Care 1996;12:19 |
392 |
| Hillman A, Eisenberg J, auly M, et al. Sounding board: Avoiding bias in the conduct and reporting of cost-effectiveness research sponsored by pharmaceutical companies. New Eng J Med 1991;324:1362-5. |
669 |
| Hornberger J, Wrone E. When to base clinical policies on observational versus randomized trial data. Ann Intern Med 1997;127:697-703. |
438 |
| Hylan T, Kotsanos J, Anderson J, Brown S, Copley-Merriman C, Egbuonu-Davis L, Heiligenstein J, Overhage J, Whiteside R. Comparison of a decision analytic model with results from a naturalistic economic clinical trial: An application to evaluating alternative antidepressants. The American Journal of Managed Care 1996;2:1211-23. |
656 |
| Iezzoni LI. Assessing quality using administrative data. Ann Intern Med 1997;127( 8 Pt 2):665-74. |
359 |
| IMS Pharma Strategy Group. Health economics in the USA: expectations, applications and future directions. IMS America. 1998. |
490 |
| International Committee of Medical Journal Editors. Uniform requirements for manuscripts submitted to biomedical journals. New Eng J Med 1997;336(4):309-15. |
393 |
| International Society for Pharmacoepidemiology. Good research practice guidelines. Pharmacoepidemiology and Drug Safety 1996;5:333-8. |
470 |
| Ioannides-Demos LL, Eckert GM, McLean AJ. Pharmacoeconomic consequences of measurement and modification of hospital drug use. Pharmacoeconomics 1992;2(1):15-33. |
465 |
| Iskedjian M, Trakas K, Bradley CA, Addis A, Lanctot KL, Kruk D, Ilersich AL, Einarson TR. Quality assessment of economic evaluations published in pharmacoeconomics - the first four years (1992 to 1995). Pharmacoeconomics 1997;12(6):85-694. |
394 |
| Jacobs P, Bachynsky J, Baladi JF. A comparative review of pharmacoeconomic guidelines. Pharmacoeconomics 1995;8(3):182-9. |
79 |
| James S, Waddington C. Capacity building in health economics opportunities for training in developing countries. Health Economics 1996;5:473-8. |
455 |
| Kassirer JP, Angel M. The journal's policy on cost-effectiveness analyses. New Eng J Med 1994;331(10):669-70. |
91 |
| Kassirer JP, Angell M. Cost-effectiveness analyses - the Journal's policy on cost-effectiveness analyses. Letters. New Eng J Med 1995;332(2):123-5. |
456 |
| Katz BP. Biostatistics to improve the power of large databases. Ann Intern Med 1997;127:769 |
450 |
| Kennedy P. The MIT Press, editors.A Guide to Econometrics. 3rd. ed. Cambridge: 1992; 9, Violating Assumption Four: Measurement Errors and Autoregression. p. 134-50. |
658 |
| Kozma CM, Reeder CE, Schulz R. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clinical Therapeutics 1993;15(6):1121-32. |
433 |
| Laine C. Coming to grips with large databases. Ann Intern Med 1997;127(number 8 (part 1)):645-7. |
627 |
| Lair TJ. Using retrospective database in the design of prospective clinical and economic studies. Drug Information Journal 1996;30:679-91. |
395 |
| Langley PC. Outcomes research and modeling therapeutic interventions for economic evaluations. Clinical Therapeutics 1994;16(3):538-53. |
397 |
| Langley PC. Therapy evaluation, patient distribution, and cost-outcomes ratios. Clinical Therapeutics 1995;17(2):341-7. |
435 |
| Langley, P.C. and Martin, R.E. Integrated Pharmaceutical Services and Foundation Health Corporation. Guidelines for Formulary Submissions. 1996. |
425 |
| Langley PC. The November 1995 revised Australian guidelines for the economic evaluation of pharmaceuticals. Pharmacoeconomics 1996;9(4):341-52. |
77 |
| Langley PC. The future of pharmacoeconomics: a commentary. Clinical Therapeutics 1997;19(4):762-9. |
396 |
| Langley PC. Pharmacoeconomics - achieving Gold Standards. London: Financial Times Healthcare; 1997.466Langsdale T. How do customers judge the quality of pharmacoeconomic studies? Pharmacoeconomics and Outcomes News 1996;13 January:3-4. |
408 |
| Lazaridis EM. Database standardization, linkage, and the protection of privacy. Ann Intern Med 1997;127(8):696 |
427 |
| Lee J, Sanchez L. Interpretation of "cost-effectiveness" and soundness of economic evaluations in the pharmacy literature. American Journal of Hospital Pharmacy 1991;48:2622-7. |
671 |
| Liang MH, Shadick N. Feasibility and utility of adding disease-specific outcome measures to administrative databases to improve disease management. Ann Intern Med 1997;127:739-42. |
431 |
| Lillard LA, Farmer MM. Linking medicare and national survey data. Ann Intern Med 1997;127:691-5. |
439 |
| Lock S. Communicating science to practitioners (abstract). Presented at the annual meeting of the International Society of Technology Assessment in Health Care 1993;9:12. |
467 |
| Longnecker, M.P. Meta-analysis. In, Tools for Evaluating Health Technologies. BP-H-142. Washington, DC. Congress, Office of Technology Assessment, US Government Printing Office. 1995. |
488 |
| Luce BR. Cost-effectiveness analysis - obstacles to standardisation and its use in regulating pharmaceuticals. Pharmacoeconomics 1993;3(1):1-9. |
400 |
| Luce BR, Simpson K. Methods of cost-effectiveness analysis: areas of consensus and debate. Clinical Therapeutics 1995;17(1):109-25. |
401 |
| Luce BR. Working toward a common currency: is standardization of cost-effectiveness analysis possible? Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology 1995;10(Suppl 4):19-22. |
57 |
| Luce BR, Lyles CA, Rentz AM. The view from managed care pharmacy. Health Affairs 1996;15(4):1-9. |
398 |
| Luce BR, Hillman AL. When is a cost-effectiveness claim valid? How much should the FDA care? The American Journal of Managed Care 1997;3(11):1660-6. |
399 |
| Lyles A, Luce BR, Rentz AM. Managed care pharmacy, socioeconomic assessment and drug adoption decisions. Social Science and Medicine 1997;45(4):511-21. |
402 |
| Martin PA. Writing a useful literature review for a quantitative research project. Applied Nursing Research 1997;10(3):159-62. |
403 |
| Mason J. Reporting guidelines for economic studies. Health Economics 1995;4:85-94. |
468 |
| Mason J. The generalizibility of pharmacoeconomic studies. Pharmacoeconomics 1997;11(6):503-14. |
404 |
| Matchar DB, Samsa GP, Matthews JR, Ancukiewicz M, Parmigiani G, Hasselblad V, Wolf PA, D'Agostino RB, Lipscomb J. The stroke prevention policy model: linking evidence and clinical decisions. Ann Intern Med 1997;127:704-11. |
440 |
| Mauskopf J. Industry responsibility in interactive computer modeling. Medical Care 1996;34:165-72. |
430 |
| McClellan M, McNeil B, Newhouse J. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables. JAMA 1994;272:859-66. |
662 |
| McClellan M. Uncertainty, health-care technologies, and health-care choices. The Economics of Health and Health Care 1995;85(2):38-44. |
663 |
| McDonald CJ, Overhage JM, Dexter P, Takesue BY, Dwyer DM. A framework for capturing clinical data sets from computerized sources. Ann Intern Med 1997;127:675-82. |
436 |
| McGhan WF, Lewis NJ. Guidelines for pharmacoeconomic studies. Clinical Therapeutics 1992;14(3):486-94; discussion 485. |
71 |
| McGhan WF, Briesacher BA. Implementing pharmacoeconomic outcomes management. Pharmacoeconomics 1994;6(5):412-6. |
406 |
| McGhan WF. Quality of Life Considerations in Clinical Trials, B Spilker, Editor. 2nd ed. Philadelphia: Lippincott-Raven Press; 1996;Using decision analysis approaches to integrate quality of life and cost data in drug therapy selection. |
462 |
| McGhan WF. Pharmacoeconomics and outcomes research - visions for the 21st century. Clinical Therapeutics 1996;18:1-4. |
405 |
| McGhan WF. Guidelines and pitfalls in pharmacoeconomics. The Journal of Management and Economics 1998;?:3-6. |
424 |
| McHorney CA. Generic health measurement: past accomplishments and a measurement paradigm for the 21st century. Ann Intern Med 1997;127:743-50. |
446 |
| Mullins, C.D. An Update of Pharmacoeconomic Guidelines and Principles. Presented at the ISPOR Conference, Issues in Pharmacoeconomics, Crystal City, VA, 18 February. 1998. |
426 |
| Nerenz DR. Measuring plans and measuring health. Ann Intern Med 1997;127:751. |
447 |
| Neumann P, Zinner D. The FDA's oversight of pharmacoeconomic claims. Risk in Perspective 1995;3(7):1-2. |
407 |
| Neumann PJ, Zinner DE, Paltiel AD. The FDA and regulation of cost-effectiveness claims. Health Affairs 1996;15(3):54-71.84 |
| O'Brien B. Economic evaluation of pharmaceuticals - Frankenstein's monster or vampire of trials? Medical Care 1996;34(12):D599-DS108. |
409 |
| O'Brien B, Drummond MF, Labelle R, Willan A. In search of power and significance: Issues in design and analysis of stochastic cost-effectiveness studies in healthcare. Medical Care 1994;32:150-63. |
476 |
| Oster G, Menzin J, Epstein RS, et al. Controlled Clinical Trials. New York, NY: Elsevier Science Inc.; 1994; 16, A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the cholesterol reduction intervention study (CRIS). |
365 |
| Palmer RH. Process-based measures of quality: the need for detailed clinical data in large health care databases. Ann Intern Med 1997;127:733-8. |
445 |
| Paltiel AD, Neumann PJ. Why training is the key to successful guideline implementation. Pharmacoeconomics 1997;12(3):297-302. |
410 |
| Pharmaceutical Research and Manufacturers of America. Methodological and conduct principles for pharmacoeconomic research. 1995. |
423 |
| Potosky A, Riley G, Lubitz J, Mentnech R, Kessler L. Potential for cancer related health services using a linked Medicare tumor registry database. Medical Care 1993;31:732-48. |
666 |
| Powe, N.R. and Griffiths, R. Clinical-economic trials. In, Tools for Evaluating Health Technologies. BP-H-142. Washington, DC. Congress, Office of Technology Assessment, US Government Printing Office. 1995. |
489 |
| Prevention Effectiveness Technical Work Group. A practical guide to prevention effectiveness: decision and economic analyses. Atlanta, GA. Centers for Disease Control, US Department of Health and Human Services. 1998. |
420 |
| Pringle M, Ward P, Chilvers C. Assessment of the completeness and accuracy of computer medical records in four practices committed to recording data on computer. British Journal of General Practice 1995;45:537-41. |
429 |
| Ray WA. Policy and program analysis using administrative databases. Ann Intern Med 1997;127:712-8. |
441 |
| Reeder CE. Overview of pharmacoeconomics and pharmaceutical outcomes evaluations. American Journal of Health-System Pharmacists 1995;52(Suppl 4):5-8. |
432 |
| Reinhardt UE. Making economic evaluations respectable. Social Science and Medicine 1997;45(4):555-62. |
411 |
| Robins J, Mark S, Newey W. Estimating exposure effects by modelling the expectation of exposure conditional on confounders. Biometrics 1992;48:479-95. |
660 |
| Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. Journal of the American Statistical Association 1984;79(387):516-24. |
659 |
| Rothman KJ. Conflict of interest - the new McCarthyism in science. JAMA 1993;269(21):2782-4. |
412 |
| Rovira J, Antonanzas F. Economic analysis of health technologies and programmes - a Spanish proposal for methodological standardisation. Pharmacoeconomics 1995;8(3):245-52. |
413 |
| Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997;127(Pt 2):757-63. |
366 |
| Sackett D. Bias in analytic research. Journal of Chronic Diseases 1979;32:51-63. |
655 |
| Sacristan JA, Soto J, Galende I. Evaluation of pharmacoeconomic studies: utilization of a checklist. The Annals of Pharmacotherapy 1993;27:1126-33. |
192 |
| Sanchez LA. Expanding the role of pharmacists in pharmacoeconomics - why and how? Pharmacoeconomics 1994;5(5):367-75.414 |
| Sanchez LA. Pharmacoeconomics and formulary decision making. Pharmacoeconomics 1996;9 (Suppl 1):16-25.75 |
| Schulman KA, Rubinstein LE, Click HA, Eisenberg JM. Relationships between sponsors and investigators in pharmacoeconomic and clinical research. Pharmacoeconomics 1995;7(3). |
415 |
| Schulman KA, Liana T, Yabroff K. Economic assessment within the clinical development program. Medical Care 1996;34(Suppl 129):89-95. |
469 |
| Selby JV. Linking automated databases for research in managed care settings. Ann Intern Med 1997;127:719-24. |
442 |
| Simon GE, Vonkorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, Wagner EH. Initial antidepressant choice in primary care. JAMA 1996;275(24):1897-902. |
364 |
| Slogan F, Whetten-Goldstein K, Wilson. Hospital pharmacy decisions, cost containment, and the use of cost effectiveness analysis. Social Science and Medicine 1997;45(4):523. |
477 |
| Smith DM. Database research: is happiness a humongous database? Ann Intern Med 1997;127(8 (pt 2)):725. |
443 |
| Sox H; Blatt M; Higgins M, et al. Medical Decision Making. Butterworths; 1988. |
473 |
| Spilker B. Use and abuse of pharmacoeconomic trials. Drug News and Perspectives 1994;7(6):363-9. |
481 |
| Spoeri RK, Ullman R. Measuring and reporting managed care performance: lessons learned and new initiatives. Ann Intern Med 1997;127:726-32. |
444 |
| Staquet M, Berzon R, Osoba D, Machin D. Guidelines for reporting results of quality of life assessments in clinical trials. Quality of Life Research 1996;5(5):496-502.83 |
| Stergachis, A., Gardner, J.S., Sullivan, S.D. et al. What are the training needs for developing research skills in pharmaceutical outcomes research? Paper presented at invitational conference, Patient Outcomes Interventions: A Scientific Foundation for the Future. American Pharmaceutical Association, November. 1994. |
453 |
| Szczepura A, Kankaanpaa J. Interests in health care technology assessment (HCTA) and HCTA training needs in eight European countries: Comett-Assess. Soc Sci Med 1994;38(12):1679-88. |
416 |
| Taskforce on principles for economic analysis of health care technology. Economic analysis of healthcare technology: a report on principles. Ann Intern Med 1995;123(1):61-70. |
479 |
| Temple, R. and O'Neill, R. Principles for the review of pharmacoeconomic promotion. Food and Drug Administration. 1995;421Testa M, Lenderking W. Interpreting pharmacoeconomic and quality-of-life clinical trial data for use in therapeutics. Pharmacoeconomics 1992;2(2):107-17. |
480 |
| The MEDSTAT Group. A guide for States to assist in the collection and analysis of medicaid managed care data. Prepared for the Health Care Financing Administration. 1997; 500-92-0035. |
665 |
| Thomas N. The role of pharmacoeconomics in disease management. A pharmaceutical benefit management company perspective. Pharmacoeconomics 1996;9 (Suppl 1):9-15. |
74 |
| Udvarhelyi S, Colditz GA, Epstein AM. Cost-effectiveness and cost-benefit analyses in the medical literature - are the methods being used correctly? Ann Intern Med 1992;116:238-44. |
417 |
| Weinberger M, Hui SL, aine C. Measuring quality, outcomes, and cost of care using large databases. Perspectives from the Sixth Regenstrief Conference. Ann Intern Med 1997;127(number 8 (part 2)):665-774. |
626 |
| Weinstein MC; Fineberg H; Frazier A, et al. Clinical Decision Analysis. Philadelphia: WB Saunders; 1980. |
474 |
| Weinstein MC. Principles of cost-effective resource allocation in healthcare organisations. International Journal of Technology Assessment in Health Care 1990;6:93-103. |
472 |
| Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276(15):1253-8. |
113 |
| Wells NEJ. Regulation of the pharmaceutical industry - and now pharmacoeconomic research? Pharmacoeconomics 1992;2(6):435-9. |
418 |
| Whittle, J. Large administrative database analysis. In, Tools for Evaluating Health Technologies. BP-H-142. Washington, DC. Congress, Office of Technology Assessment, US Government Printing Office. 1995. |
486 |
| Yee GC, Hillman AL. Applied pharmacoeconomics - when can publication be legitimately withheld? Pharmacoeconomics 1997;12(5):511-6. |
419 |
| Zhou X-H, Melfi CA, Hui SL. Methods for comparison of cost data. Ann Intern Med 1997;127:752-6. |
448 |
